Galvanize Therapeutics Begins U.S. Clinical Study Using Aliya™ Pulsed Electric Field (PEF) for Stage IV Non-Small Cell Lung Cancer or Metastasis to the Lung
Nine Square Therapeutics Awarded $4.5 Million Grant from The Michael J. Fox Foundation to Advance Development of Novel Parkin Activators
Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine
BRIXADI® (buprenorphine) Extended-Release Injection for Subcutaneous Use (CIII) is Now Available in the U.S. for the Treatment of Moderate to Severe Opioid Use Disorder
Aulos Bioscience Raises $20 Million in Series A Extension Financing From Apple Tree Partners
Apple Tree Partners Recruits Noted Biotech Entrepreneur and Computer-Aided Drug Design Pioneer Matthew P. Jacobson, Ph.D., as New Venture Partner
Replicate Bioscience Appoints Rachael Lester as Chief Business Officer
Intergalactic Therapeutics Announces Positive Results for Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies in Non-Human Primates
Galvanize Therapeutics Completes Enrollment in Pivotal Trial of RheOx® System for Chronic Bronchitis
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
Galvanize Announces License Agreement and Partnership with Energenx Medical for its Technologies in China
Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells
FDA News Release: FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder
Intergalactic Therapeutics to Host Virtual KOL Investor Event on May 23, 2023
Intergalactic Therapeutics to Present Preclinical Data Highlighting Potential of Its Non-Viral Gene Therapy Platform at the American Society of Gene and Cell Therapy 26th Annual Meeting
Ascidian Therapeutics to Present New Data From Its Lead Program Targeting ABCA4 Retinopathies at the ASGCT 2023 Annual Meeting
With $75 Million from Apple Tree Partners, Initial Therapeutics Launches to Create a New Kind of Drug Designed to Stop the Formation of Difficult-to-Drug Protein Targets
Intergalactic Therapeutics to Present Updated Data From Its Non-Viral Gene Therapy Platform at the 2023 Retinal Cell and Gene Therapy Innovation Summit
Replicate Bioscience Presents Preclinical srRNA Data at the American Association for Cancer Research Annual Meeting 2023
Ascidian Therapeutics to Present Data From Its Lead Program Targeting ABCA4 Retinopathies at the Retinal Cell and Gene Therapy Innovation Summit and ARVO 2023 Annual Meeting
Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic
Marengo Therapeutics to Present a Late-Breaking Abstract at AACR Annual Meeting 2023 Highlighting Broad Application of its Novel TCR Vβ Targeting Platform
Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer
Intergalactic Therapeutics Announces Positive Preclinical Results of Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies
Replicate Bioscience Shares New Preclinical srRNA Data at American Association for Cancer Research Annual Meeting 2023
New Interventional Oncology Data Show Potential for Aliya™ Pulsed Electric Field (PEF) System in Treatment of Solid Tumors
Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer
Galvanize Therapeutics Announces First Human Use of QuickShot: A Novel Contact-Sensing, Large Area, Focal Pulsed Electric Field Mapping and Ablation Catheter
Gene editing: DNA versus RNA (Drug Discovery News)
First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors
Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy
Why I invited investors into my lab: Adendra Therapeutics co-founder Caetano Reis e Sousa in conversation with The Francis Crick Institute
ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells
Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer
Ascidian Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Braeburn Applauds Passage of Significant Advancements in the Treatment of Opioid Use Disorder
FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Marengo Therapeutics Presents Preclinical Data Supporting Clinical Investigation of its Lead Asset, STAR0602, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Galvanize Therapeutics Presents Clinical Data Using Pulsed Electric Field (PEF) Energy for Non-Small Cell Lung Cancer
Aulos Bioscience Announces FDA Clearance of IND Application for AU-007, a Novel Immunotherapy for the Treatment of Solid Tumors
Marengo Therapeutics Presents Preclinical Proof-of Concept Data for STAR0602, a First-in-class Selective T cell Activator, at the 34th EORTC-NCI-AACR Symposium 2022
New Biotechnology Combines Targeted and Immune Therapies to Kill Treatment-resistant Cancer Cells
Marengo Therapeutics to Give Plenary Oral Presentation at 34th EORTC-NCI-AACR (ENA) Symposium on Lead Program, STAR0602 and Present Additional Data at the SITC Conference Featuring its Vβ-Targeted Selective T Cell Ac
Ascidian Therapeutics Launches to Rewrite RNA
Aulos Bioscience to Present Initial Safety Data From First-in-Human Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nereid Therapeutics Co-Founder Clifford Brangwynne Awarded 2023 Breakthrough Prize in Life Sciences
How 3 companies merged and raised $100M to treat range of diseases by pulsing cells (San Francisco Business Times)
Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into Human Trials in Solid Tumors and Enters Cooperative Research and Development Agreement with the National Cancer Institute
Galvanize Therapeutics Announces Merger to Create the Premier Pulsed Electric Field Therapy Company and Completion of $100 Million Series B Financing
Nine Square Therapeutics Appoints John Hood to Board of Directors
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates from Marengo’s STAR Platform into the Clinic
Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale Up Genomic Medicines
Replicate Bioscience Expands Leadership Team, Appointing Zelanna Goldberg, M.D., as Chief Medical Officer and Mohit Trikha, Ph.D., to Board of Directors
Marengo Therapeutics Announces Formation of Scientific Advisory Board to Advance the Company's Development of Novel Therapeutics for Precision Immuno-Oncology
Marengo Therapeutics Expands Executive Leadership Team with Svetlana Makhni Joining as Chief Financial Officer
Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)
Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting
Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic
Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors
Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting
Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors
Marengo Therapeutics to Participate in Investor, Scientific, Industry Conferences
Apple Tree Partners Donates to Humanitarian Relief Efforts in Ukraine
ATP Statement on War in Ukraine
Aulos Bioscience Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Anti-Tumor Activity of Novel IL-2 Therapeutic AU-007
Gala Therapeutics Announces First Commercial Cases Worldwide with RheOx® System for Chronic Bronchitis
Intergalactic Therapeutics Announces Scientific Advisory Board Membership
Nine Square Therapeutics Appoints Robert Paul as CEO
Marengo Therapeutics to Present at Annual J.P. Morgan Health Care Conference
ATP Launches Adendra Therapeutics, a New Kind of Immunotherapy Company Deploying Novel Insights into Dendritic Cell Biology, with $53M Series A
Aulos Bioscience Presents Preclinical Data Demonstrating Anti-Tumor Activity of AU-007, a Novel IL-2 Therapeutic, at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform
Nereid Therapeutics Announces Scientific Advisory Board Membership
Nereid Therapeutics Announces Appointments of Laura Forese and Rupert Vessey to Its Board of Directors
ATP Names Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology
ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding
Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
ATP Founds New Center for CRISPR Target Discovery in Collaboration with Innovative Genomics Institute (IGI) and Jennifer Doudna
Galaxy Medical Enrolls First Patients in SPACE-AF Study
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
Data from Multiple Studies Show Positive Outcomes with Gala Therapeutics' RheOx™ System for Chronic Bronchitis
Galaxy Medical Releases ECLIPSE-AF Remapping Data at Stanford Biodesign Retreat and Update on System Interoperability
FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
Gala Therapeutics Announces First Patients Enrolled in Pivotal Trial of RheOx™ System for Chronic Bronchitis
Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer
Nine Square: Taking Aim at Organelle Function in Movement Disorders with Computation and Imaging (BioCentury Emerging Company Profile)
Galaxy Medical and Japan Lifeline Enter Distribution Agreement For Novel Pulsed Electric Field Focal Ablation Catheter
Breathing Life into Britain’s Life-Sciences Industry (The Economist)
Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors
Galaxy Medical Receives $18 Million from ATP to Advance Development of Its Novel Pulsed Electric Field Ablation Therapy for Cardiac Arrhythmias
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Doug Godshall to Chair Gala Therapeutics Board of Directors
Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
ATP Forms ATP V With $1 Billion in New Capital Commitments
Nereid Therapeutics Launches: ATP $50M Series A NewCo Co-Founded with Brangwynne, Pioneer of Biomolecular Condensates Field
First Patients Treated with Galaxy Medical’s CENTAURI™ Pulsed Electric Field Cardiac Ablation System
Gala Therapeutics’ RheOx™ System Showcased at Virtual European Respiratory Society Congress
Results Published from Multicenter Study of Gala Therapeutics' Minimally Invasive RheOx™ System in Patients with Chronic Bronchitis
Four Questions for Neurology Startups as Venture Investors Pour Millions into the Field (STAT News)
Apple Tree Partners Founds Nine Square Therapeutics to Pioneer Novel Treatments for Movement Disorders
Apple Tree Partners Portfolio Company Corvidia Therapeutics to be Acquired by Novo Nordisk